Federal regulators will not act against licensed compounders making six peptides, including mitochondrial MOTS-c — for now

Edited by Samael A. Tejada, Founder & Editor-in-Chief

Access and evidence are different questions, and this policy answers only the first. It moves six popular peptides from the gray market into licensed pharmacies under conditions — which addresses the real harms of unlabeled imports — while leaving the second question, whether these peptides work and are safe at the doses people use, exactly where the FDA's staff left it: unproven. Both halves of that sentence matter.

What exactly does the policy allow, and for whom?

The policy covers compounding under section 503A by state-licensed pharmacies, federal facilities and licensed physicians, for six bulk substances: BPC-157 acetate (subcutaneous, intramuscular, oral or topical), TB-500 acetate (subcutaneous or intramuscular), epitalon acetate (subcutaneous or intramuscular, in intermittent courses), Semax free base (intranasal), KPV acetate (topical or oral) and MOTS-c acetate (subcutaneous or intramuscular). Enforcement discretion applies only when detailed conditions are met — peptide identity and route limits, FDA-registered and CGMP-compliant ingredient manufacturers, certificates of analysis and testing, patient-specific prescriptions, single-active-ingredient formulations, labeling, and adverse-event and product-quality reporting. Compounded drugs are not FDA-approved: the agency does not review their safety, effectiveness or quality before marketing.

Why did HHS act, and who disagreed?

Health Secretary Robert F. Kennedy Jr. has publicly supported broader peptide access, calling himself a big fan of the treatments and arguing that Americans were importing unsafe products from outside regulated channels; an HHS spokesperson framed the policy as confronting the risks of black-market peptides by routing supply through licensed U.S. compounders. The July FDA advisory committee recommended allowing all six peptides in compounding. The FDA's own staff had recommended against doing so, citing insufficient evidence of safety and effectiveness — the 2023 do-not-compound listing for several of these substances cited concerns including allergic reactions, kidney damage and tumor growth. HHS initially considered a formal regulation and switched to non-enforcement; critics quoted in coverage note the directed guardrails may be hard to enforce. A two-week public comment window accompanies the policy.

What is MOTS-c, the mitochondrial peptide on the list?

MOTS-c is a small peptide encoded not in nuclear DNA but in the mitochondrial genome — one of a handful of mitochondrial-derived peptides — and it is studied for roles in metabolic regulation, insulin sensitivity and exercise capacity, largely in animal and early human work. It is the only one of the six whose claim to attention runs directly through mitochondrial biology, and its presence on the list is why this policy belongs in this edition. But the policy changes MOTS-c's legal availability, not its evidence: there is still no approved indication, no large randomized human trial establishing benefit for obesity, osteoporosis or any other marketed use, and no FDA-reviewed dosing. A prescription from a licensed physician and a vial from a licensed compounder are meaningful safety upgrades over an imported research chemical — they are not evidence the peptide works.

Where the evidence stands

• Established: The policy itself: published October 28, 2026, it extends interim enforcement discretion to 503A compounding of BPC-157, TB-500, epitalon, KPV, MOTS-c and Semax under specified conditions (registered CGMP ingredient sources, testing, patient-specific prescriptions, reporting, labeling, route limits). Compounded drugs are not FDA-approved.
• Contested: Whether the six peptides are safe and effective for their marketed uses. A July 2026 FDA advisory panel recommended allowing them in compounding; FDA scientific staff recommended against, citing insufficient safety and effectiveness evidence and prior concerns including allergic reactions, kidney damage and tumor growth.
• Absent: FDA approval of any of the six peptides for any indication, and large randomized human trials establishing clinical benefit — including for MOTS-c in obesity or osteoporosis.